266 - Why Do We Do This? Exploring the Data Behind Long-Established Practices in ID

Wednesday, October 22, 2025

3:15 PM - 4:30 PM US ET

Location: B308-B309

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Senu Apewokin, MD

Assoc Prof
University of Cincinnati
Mason, OH, United States
Caitlin Li, MD MHQS (she/her/hers)

Assistant Professor of Pediatrics
Lurie Childrens Hospital
Chicago, IL, United States

Faculty(s)

JG

Jason Gallagher, PharmD

Clinical Professor
Temple University
Philadelphia, PA, United States
Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP (she/her/hers)

Dean
1. Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, RI, United States 2. Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center, Providence, RI, United States 3. College of Pharmacy, University of Rhode Island, Kingston, RI, United States 5. Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, RI
Kingston, RI, United States
Nicolas Cortes-Penfield, MD (he/him/his)

Associate Professor Medical Director, Outpatient Parenteral Antimicrobial Therapy Program
Infectious Diseases
University of Nebraska Medical Center
Omaha, NE, United States

Disclosure(s):

Senu Apewokin, MD: Nestle/Seres: Honoraria

Caitlin Li, MD MHQS: No financial relationships to disclose.

Jason Gallagher, PharmD: AbbVie Inc: Advisor/Consultant, Honoraria; GSK/ViiV Healthcare: Advisor/Consultant, Honoraria; Invivyd: Advisor/Consultant, Honoraria; Meitheal pharmaceuticals: Advisor/Consultant, Honoraria; Merck and Company, Inc.: Advisor/Consultant, Grant/Research Support, Honoraria; Novavax, Inc.: Advisor/Consultant, Honoraria; SHIONOGI and CO., LTD.: Advisor/Consultant, Honoraria

Kerry L. LaPlante, Pharm.D., FCCP, FIDSA, FIDP: AbbVie Inc: Advisor/Consultant, Grant/Research Support; Entasis Therapeutics Inc.: Grant/Research Support; MAD-ID: Board Member; Melinta Therapuetics: Grant/Research Support; Pfizer, Inc.: Grant/Research Support; Shionogi, Inc.: Advisor/Consultant, Grant/Research Support

Nicolas W. Cortes-Penfield, MD: No financial relationships to disclose.

Learning Objectives:

At the conclusion of this session, participants will be able to:

review the evidence supporting the use of rifampin in treatment of hardware infections;
interpret the data supporting or against double antimicrobial coverage for various infectious processes;
evaluate the evidence or lack thereof supporting shorter treatment durations of bacteremia.

Presentations:

3:15 PM - 3:40 PM US ET

The Role of Rifampin in Hardware Infections
Speaker: Nicolas W. Cortes-Penfield, MD (he/him/his) – University of Nebraska Medical Center
3:40 PM - 4:05 PM US ET

Double Coverage; Do We Need It?
Speaker: Kerry L. LaPlante, Pharm.D., FCCP, FIDSA, FIDP (she/her/hers) – 1. Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, RI, United States 2. Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center, Providence, RI, United States 3. College of Pharmacy, University of Rhode Island, Kingston, RI, United States 5. Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, RI
4:05 PM - 4:30 PM US ET

IV or Not IV? That Is the Duration. An update on routes and durations of therapy for bactermia.
Speaker: Jason Gallagher, PharmD – Temple University

266 - Why Do We Do This? Exploring the Data Behind Long-Established Practices in ID ​

Moderator(s)

Faculty(s)

Learning Objectives:

Presentations:

266 - Why Do We Do This? Exploring the Data Behind Long-Established Practices in ID